Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Non-Invasive Fecal DNA Test Accurately Detects Colorectal Cancer and Precancerous Lesions

By LabMedica International staff writers
Posted on 30 Mar 2023

Colorectal cancer is a highly prevalent form of cancer worldwide, with over 1. More...

9 million new cases reported in 2020, and is a leading cause of cancer-related deaths. Fortunately, regular screening can help prevent many cases of colorectal cancer. Common screening methods include both invasive procedures like flexible sigmoidoscopy and colonoscopy, as well as non-invasive options such as blood tests and fecal-based tests. Currently, fecal-based tests available include the guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and the new, multitarget stool DNA test.

The newer fecal DNA testing, being able to detect specific DNA changes found in cancerous tumors or precancerous polyps, is generally considered more sensitive than FIT. Aberrant DNA methylation is an early molecular change that is common, stable, and detectable in small amounts of DNA during carcinogenesis. Consequently, cells from precancerous and cancerous lesions with these mutations are often shed as DNA biomarkers into the stool. Thus, fecal DNA testing has the potential to outperform FIT not only in detecting colorectal cancer but, more significantly, in detecting precancerous adenoma.

BGI Genomics (Shenzhen, China) has developed a non-invasive fecal DNA test, known as COLOTECTTM 1.0, to detect colorectal cancer and precancerous lesions. The test employs multiplex methylation-specific PCR (MSP) technology to track abnormal DNA-methylation biomarkers in stool samples. Detection of methylated DNA as a tumor biomarker has become common in several cancer types, including colorectal cancer. The COLOTECTTM 1.0 is highly sensitive and specific, with a straightforward workflow approach and compatible with commonly used PCR platforms. The test has a 88% sensitivity for colorectal cancer and a remarkable 46% sensitivity for detecting advanced adenoma for early detection. Additionally, its specificity for non-advanced neoplasms is as high as 92%.

In case of abnormal results detected by the COLOTECT 1.0 test, patients will require additional diagnostic tests and consultations with a medical professional. The test's non-invasive and easy-to-use characteristics make it easier for patients to overcome barriers to colorectal screening. COLOTECT 1.0 has the potential to enhance colorectal cancer prevention and early detection, providing patients with better health outcomes and improved convenience. The test is CE-marked and currently available in over 20 countries in South-East Europe.

Related Links:
BGI Genomics


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.